{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:14:02Z","timestamp":1761178442295,"version":"build-2065373602"},"reference-count":30,"publisher":"Elsevier BV","issue":"6-7","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer\/Radioth\u00e9rapie"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.canrad.2015.06.005","type":"journal-article","created":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T01:49:00Z","timestamp":1441072140000},"page":"416-420","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Recommandations pour la prise en charge des cancers du canal anal"],"prefix":"10.1016","volume":"19","author":[{"given":"D.","family":"Peiffert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canrad.2015.06.005_bib0155","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.ejso.2014.07.030","article-title":"Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"40","author":"Glynne-Jones","year":"2014","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.canrad.2015.06.005_bib0160","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/ijc.25671","article-title":"Human papillomavirus genotype distribution in anal cancer in France: the EDiTH V study","volume":"129","author":"Abramowitz","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1016\/j.canrad.2015.06.005_bib0165","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/ijc.28963","article-title":"Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide","volume":"136","author":"Alemany","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1016\/j.canrad.2015.06.005_bib0170","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/jnci\/djs491","article-title":"Annual report to the Nation on the status of cancer, 1975-2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels","volume":"105","author":"Jemal","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.canrad.2015.06.005_bib0175","doi-asserted-by":"crossref","first-page":"4360","DOI":"10.1200\/JCO.2012.44.5486","article-title":"Incidence of HIV-related anal cancer remains increased despite long-term combined antiretroviral treatment: results from the french hospital database on HIV","volume":"30","author":"Piketty","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2015.06.005_bib0180","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1056\/NEJMoa1010971","article-title":"HPV vaccine against anal HPV infection and anal intraepithelial neoplasia","volume":"365","author":"Palefsky","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2015.06.005_bib0185","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.radonc.2010.11.011","article-title":"Concurrent chemoradiotherapy with 5-fluorouracil and mitomycin-C for anal carcinoma: are there differences between HIV-positive and HIV-negative patients in the era of highly active antiretroviral therapy?","volume":"98","author":"Fraunholz","year":"2011","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2015.06.005_bib0190","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.2214\/AJR.13.12256","article-title":"FDG PET\/CT in the management of colorectal and anal cancers","volume":"203","author":"Agarwal","year":"2014","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.canrad.2015.06.005_bib0195","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00384-010-1080-9","article-title":"Impact of FDG PET\/CT in the staging and the follow-up of anal carcinoma","volume":"26","author":"Vercellino","year":"2011","journal-title":"Int J Colorectal Dis"},{"key":"10.1016\/j.canrad.2015.06.005_bib0200","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/bjc.2011.274","article-title":"FDG-PET metabolic response predicts outcomes in anal cancer managed with chemoradiotherapy","volume":"105","author":"Day","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.canrad.2015.06.005_bib0205","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.ijrobp.2008.08.070","article-title":"Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring atlas","volume":"74","author":"Myerson","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2015.06.005_bib0210","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/j.ijrobp.2011.12.058","article-title":"Australasian Gastrointestinal Trials Group (AGITG) contouring atlas and planning guidelines for intensity-modulated radiotherapy in anal cancer","volume":"83","author":"Ng","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2015.06.005_bib0215","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1016\/j.ijrobp.2011.02.010","article-title":"Anal canal cancer: management of inguinal nodes and benefit of prophylactic inguinal irradiation (CORS-03 Study)","volume":"82","author":"Ortholan","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2015.06.005_bib0220","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.1002\/cncr.25901","article-title":"Intensity-modulated radiation therapy versus conventional radiation therapy for squamous cell carcinoma of the anal canal","volume":"117","author":"Bazan","year":"2011","journal-title":"Cancer."},{"key":"10.1016\/j.canrad.2015.06.005_bib0225","first-page":"39","article-title":"Intensity-Modulated Radiation Therapy vs. 3D Conformal Radiation Therapy for Squamous Cell Carcinoma of the Anal Canal","volume":"6","author":"Chuong","year":"2013","journal-title":"Gastrointest Cancer Res"},{"key":"10.1016\/j.canrad.2015.06.005_bib0230","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000348387","article-title":"Dosimetric parameters predictive of acute gastrointestinal toxicity in patients with anal carcinoma treated with concurrent chemotherapy and intensity-modulated radiation therapy","volume":"85","author":"DeFoe","year":"2013","journal-title":"Oncology."},{"key":"10.1016\/j.canrad.2015.06.005_bib0235","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ijrobp.2012.09.023","article-title":"RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal","volume":"86","author":"Kachnic","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2015.06.005_bib0240","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.canrad.2011.07.240","article-title":"Radioth\u00e9rapie conformationnelle avec modulation d\u2019intensit\u00e9 des cancers de l\u2019anus","volume":"15","author":"Peiffert","year":"2011","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2015.06.005_bib0245","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.ijrobp.2009.09.046","article-title":"Intensity-modulated radiation therapy for anal malignancies: a preliminary toxicity and disease outcomes analysis","volume":"78","author":"Pepek","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2015.06.005_bib0250","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1748-717X-7-45","article-title":"IMRT for locally advanced anal cancer: clinical experience of the Montpellier Cancer Center","volume":"7","author":"Vieillot","year":"2012","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.canrad.2015.06.005_bib0255","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.canrad.2013.12.008","article-title":"Apport de la RCMI rotationnelle et de la tomoth\u00e9rapie h\u00e9lico\u00efdale dans les cancers pelviens\u00a0: \u00e9tude dosim\u00e9trique prospective sur 51 patients","volume":"18","author":"Servagi-Vernat","year":"2014","journal-title":"Cancer Radiother"},{"year":"2013","series-title":"\u00c9valuation de la radioth\u00e9rapie conformationnelle avec modulation d\u2019intensit\u00e9 dans les cancers du col ut\u00e9rin et du canal anal [Note de cadrage\u00a0; document sur Internet]","author":"Service \u00e9valuation des actes professionnel de la Haute Autorit\u00e9 de sant\u00e9 (HAS)","key":"10.1016\/j.canrad.2015.06.005_bib0260"},{"year":"2015","series-title":"Radioth\u00e9rapie conformationnelle avec modulation d\u2019intensit\u00e9 dans le cancer du col ut\u00e9rin [Rapport d\u2019\u00e9valuation technologique\u00a0; document sur Internet]","author":"Azria","key":"10.1016\/j.canrad.2015.06.005_bib0265"},{"key":"10.1016\/j.canrad.2015.06.005_bib0270","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1200\/JCO.2011.35.4837","article-title":"Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial","volume":"30","author":"Peiffert","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2015.06.005_bib0275","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S1470-2045(13)70086-X","article-title":"Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2\u00d72 factorial trial","volume":"14","author":"James","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2015.06.005_bib0280","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ijrobp.2007.12.012","article-title":"EXTRA-a multicenter phase II study of chemoradiation using a 5 day per week oral regimen of capecitabine and intravenous mitomycin-C in anal cancer","volume":"72","author":"Glynne-Jones","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2015.06.005_bib0285","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1093\/annonc\/mdt396","article-title":"DCF (docetaxel, cisplatin and 5-fluorouracil) chemotherapy is a promising treatment for recurrent advanced squamous cell anal carcinoma","volume":"24","author":"Kim","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.canrad.2015.06.005_bib0290","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1186\/s13014-014-0240-4","article-title":"Interstitial high-dose rate brachytherapy as boost for anal canal cancer","volume":"9","author":"Falk","year":"2014","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.canrad.2015.06.005_bib0295","doi-asserted-by":"crossref","first-page":"736","DOI":"10.3109\/0284186X.2013.770599","article-title":"Impaired health-related quality of life after chemoradiotherapy for anal cancer: late effects in a national cohort of 128 survivors","volume":"52","author":"Bentzen","year":"2013","journal-title":"Acta Oncol"},{"key":"10.1016\/j.canrad.2015.06.005_bib0150","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.radonc.2013.05.037","article-title":"Faecal incontinence after chemoradiotherapy in anal cancer survivors: long-term results of a national cohort","volume":"108","author":"Bentzen","year":"2013","journal-title":"Radiother Oncol"}],"container-title":["Cancer\/Radioth\u00e9rapie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321815001572?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321815001572?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T12:24:12Z","timestamp":1761135852000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1278321815001572"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":30,"journal-issue":{"issue":"6-7","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S1278321815001572"],"URL":"https:\/\/doi.org\/10.1016\/j.canrad.2015.06.005","relation":{},"ISSN":["1278-3218"],"issn-type":[{"type":"print","value":"1278-3218"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recommandations pour la prise en charge des cancers du canal anal","name":"articletitle","label":"Article Title"},{"value":"Cancer\/Radioth\u00e9rapie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canrad.2015.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Soci\u00e9t\u00e9 fran\u00e7aise de radioth\u00e9rapie oncologique (SFRO). Published by Elsevier Masson SAS All rights reserved.","name":"copyright","label":"Copyright"}]}}